Eli Lilly has announced 2025 revenue of USD 65.2 billion, a 44% increase from the previous year, with R&D spending rising 21% to USD 13.3 billion. The company's growth was overwhelmingly driven by its GLP-1/GIP receptor agonist, tirzepatide. The diabetes version, Mounjaro, generated USD 23.0 billion in sales, a 99% increase, while the obesity treatment, Zepbound, brought in USD 13.5 billion, a 175% surge. The combined sales of these two products exceeded USD 36.5 billion for the year.

Revenue grew across all major regions, with the US market contributing USD 43.5 billion and the European market growing 62% to USD 11.6 billion. Sales in China increased 18% to USD 2.0 billion. The company's oncology drug Verzenio (abemaciclib) also performed well with sales of USD 5.7 billion. Looking ahead to 2026, which marks Lilly's 150th anniversary, the company plans to advance trials for its oral GLP-1 agonist orforglipron and GIPR×GLP-1R×GCGR triple agonist retatrutide, forecasting total revenue between USD 80.0 billion and USD 83.0 billion.

PharmCube's NextBiopharm® database shows that Lilly is developing retatrutide in 14 different indications. Click here to request a free trial for NextBiopharm®.